1. Home
  2. VERI vs ACRV Comparison

VERI vs ACRV Comparison

Compare VERI & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veritone Inc.

VERI

Veritone Inc.

N/A

Current Price

$0.55

Market Cap

80.2M

Sector

Technology

ML Signal

N/A

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

N/A

Current Price

$1.91

Market Cap

74.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VERI
ACRV
Founded
2014
2018
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.2M
74.0M
IPO Year
2017
2022

Fundamental Metrics

Financial Performance
Metric
VERI
ACRV
Price
$0.55
$1.91
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
$5.38
★ $11.50
AVG Volume (30 Days)
★ 5.5M
326.7K
Earning Date
11-05-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 15.13
EPS
★ N/A
N/A
Revenue
★ $92,637,000.00
N/A
Revenue This Year
$11.35
N/A
Revenue Next Year
$32.92
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.58
$1.27
52 Week High
$9.42
$3.56

Technical Indicators

Market Signals
Indicator
VERI
ACRV
Relative Strength Index (RSI) 26.76 46.59
Support Level N/A $1.61
Resistance Level $1.56 $2.21
Average True Range (ATR) 0.11 0.12
MACD -0.07 -0.02
Stochastic Oscillator 0.73 30.43

Price Performance

Historical Comparison
VERI
ACRV

About VERI Veritone Inc.

Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has presence in the United States, the United Kingdom, France, Australia, Israel, and India.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: